ARK Genomic Revolution ETF

ARKG

Market cap $1.04B

Overview Fund Activity

25.60 USD

-0.59

2.25%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

25.70

+0.10

0.39%

1 day

-2.25%

5 days

-0.27%

1 month

6.31%

3 months

8.25%

6 months

11.45%

Year to date

4.66%

1 year

1.11%

5 years

-57.59%

10 years

18.24%

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

9% more capital invested

Capital invested by funds: $480M [Q1] → $525M (+$45.4M) [Q2]

9% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 32

0% less funds holding

Funds holding: 209 [Q1] → 208 (-1) [Q2]

7% less call options, than puts

Call options by funds: $107M | Put options by funds: $116M

3.23% less ownership

Funds ownership: 52.95% [Q1] → 49.73% (-3.23%) [Q2]

41% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 66

See Fund Rankings

Financial journalist opinion

ARKG: I'm Holding Off Buying For These 3 Reasons

I maintain a hold rating on ARK Genomic Revolution ETF due to unprofitable top holdings, high operating costs, and limited approved treatments despite revenue growth. ARKG's high expense ratio and lack of dividend yield make it less attractive compared to peer genomic ETFs with better performance and lower fees. Top holdings like Tempus AI, CRISPR Therapeutics, and Twist Bioscience are either overvalued or struggle with profitability, limiting ARKG's upside.

ARKG: I'm Holding Off Buying For These 3 Reasons

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft

I reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward profile, and focus on the genomics revolution, though it lacks a dividend yield. The ETF has rebounded 42% off April lows, outperforming the S&P 500, but faces seasonal headwinds and resistance near $28-$31.

ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft

24/7 Wall Street

Cathie Wood Comeback: These 2 Ark ETFs are Sailing Higher Again

It's probably time to give Cathie Wood the benefit of the doubt as the tides turn back in disruptive innovation's favor.

Cathie Wood Comeback: These 2 Ark ETFs are Sailing Higher Again

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Zacks Investment Research

Best-Performing ETFs of Last Week

Wall Street was upbeat last week, despite the release of hot January inflation data.

Best-Performing ETFs of Last Week

24/7 Wall Street

2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year

Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.

2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year

Can Health Care ETFs Aid Your Portfolio?

The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.

Can Health Care ETFs Aid Your Portfolio?

24/7 Wall Street

Cathie Wood's Top Biotech Plays for February

Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.

Cathie Wood's Top Biotech Plays for February

See News Rankings

Charts implemented using Lightweight Charts™